Inhibikase Therapeutics, Inc.

Healthcare · Biotechnology · United States

Last price 1.55 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 282.22M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics to modify the course of cardiopulmonary diseases, with a primary focus on pulmonary arterial hypertension (PAH), a progressive, life-threatening disease characterized by pulmonary vascular remodeling and elevated pulmonary vascular resistance. It offers IKT-001, a novel oral prodrug of imatinib mesylate designed for the treatment of pulmonary arterial hypertension (PAH) was designed to improve areas of the molecule that might play a role...